These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 27900102)

  • 1. Comparison of cost-effectiveness of regorafenib and trifluridine/tipiracil combination tablet for treating advanced and recurrent colorectal cancer.
    Kimura M; Usami E; Iwai M; Go M; Teramachi H; Yoshimura T
    Mol Clin Oncol; 2016 Nov; 5(5):635-640. PubMed ID: 27900102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales.
    Bullement A; Underhill S; Fougeray R; Hatswell AJ
    Clin Colorectal Cancer; 2018 Mar; 17(1):e143-e151. PubMed ID: 29110922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
    Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
    Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regorafenib and trifluridine/tipiracil in real clinical practice.
    García-Beloso N; Romero-Ventosa EY; Gayoso-Rey M; López-López A; Robles-Torres D; de Castro NM; Piñeiro-Corrales G
    J Cancer Res Ther; 2022 Dec; 18(Supplement):S367-S373. PubMed ID: 36510990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Cost-utility Analysis of Regorafenib and Trifluridine/Tipiracil in The Treatment of Metastatic Colorectal Cancer in Japan.
    Kashiwa M; Matsushita R
    Clin Ther; 2020 Jul; 42(7):1376-1387. PubMed ID: 32653227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic Review and Meta-Analysis of Multitargeted Tyrosine Kinase Inhibitors in Patients With Intractable Metastatic Colorectal Cancer.
    Gao Z; Cao C; Bao Y; Fan Y; Chen G; Fu P
    Technol Cancer Res Treat; 2020; 19():1533033820943241. PubMed ID: 32914703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-escalation strategy in refractory metastatic colorectal cancer: A change in terms of cost-effectiveness.
    Giuliani J; Fiorica F; Ponturo G; Azzurro M; Ruzzenente A; Bonetti A
    J Oncol Pharm Pract; 2021 Jun; 27(4):974-977. PubMed ID: 33541208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment.
    Niisato Y; Moriwaki T; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Hatachi Y; Suto T; Sugimoto N; Shimada Y
    Anticancer Res; 2021 Apr; 41(4):2203-2207. PubMed ID: 33813435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center.
    Patel AK; Abhyankar R; Brais LK; Duh MS; Barghout VE; Huynh L; Yenikomshian MA; Ng K; Fuchs CS
    Oncologist; 2021 Dec; 26(12):e2161-e2169. PubMed ID: 34406678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of trifluridine and tipiracil hydrochloride in the treatment of metastatic colorectal cancer in Greece.
    Gourzoulidis G; Maniadakis N; Petrakis D; Souglakos J; Pentheroudakis G; Kourlaba G
    J Comp Eff Res; 2019 Feb; 8(3):133-142. PubMed ID: 30547679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Regorafenib and Trifluridine and Tipiracil Hydrochloride Can Potentially Improve the Survival Time for Patients with Advanced or Recurrent Colorectal Cancer].
    Oki M; Nakamura A; Shinamura N; Sugaya T; Takagi K; Sugaya M
    Gan To Kagaku Ryoho; 2018 Sep; 45(9):1297-1303. PubMed ID: 30237371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer Patients.
    Unseld M; Fischöder S; Jachs M; Drimmel M; Siebenhüner A; Bianconi D; Kieler M; Puhr H; Minichsdorfer C; Winder T; Prager GW
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32517383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study.
    Chida K; Kotani D; Nakamura Y; Kawazoe A; Kuboki Y; Shitara K; Kojima T; Taniguchi H; Watanabe J; Endo I; Yoshino T
    Ther Adv Med Oncol; 2021; 13():17588359211009143. PubMed ID: 33959196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.
    Moriwaki T; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Hatachi Y; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Oki E; Komatsu Y; Tsuji A; Tsuchihashi K; Sakai D; Ueno H; Tamura T; Yamashita K; Shimada Y
    Int J Clin Oncol; 2020 Apr; 25(4):614-621. PubMed ID: 31838590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan.
    Takushima Y; Igarashi A; Yoshihara H; Shitara K; Doi T
    Jpn J Clin Oncol; 2021 Aug; 51(9):1383-1390. PubMed ID: 34128042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution.
    Kotani D; Shitara K; Kawazoe A; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Doi T; Ohtsu A; Yoshino T
    Clin Colorectal Cancer; 2016 Sep; 15(3):e109-15. PubMed ID: 26723516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Observational Study of Trifluridine/Tipiracil-Containing Regimen Versus Regorafenib-Containing Regimen in Patients With Metastatic Colorectal Cancer.
    Hsieh MC; Rau KM; Lin SE; Liu KW; Chiu CC; Chen CI; Song LC; Chen HP
    Front Oncol; 2022; 12():867546. PubMed ID: 35664763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective study of regorafenib and trifluridine/tipiracil efficacy as a third-line or later chemotherapy regimen for refractory metastatic colorectal cancer.
    Tanaka A; Sadahiro S; Suzuki T; Okada K; Saito G; Miyakita H
    Oncol Lett; 2018 Nov; 16(5):6589-6597. PubMed ID: 30344762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness, safety, and prognostic factors of trifluridine/tipiracil for the treatment of patients with metastatic colorectal cancer in routine clinical practice.
    Martínez-Pérez J; Espinosa-Montaño M; Luque-Caro N; Aviñó-Tarazona V
    J Gastrointest Oncol; 2023 Apr; 14(2):692-704. PubMed ID: 37201039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands.
    Kwakman JJM; Vink G; Vestjens JH; Beerepoot LV; de Groot JW; Jansen RL; Opdam FL; Boot H; Creemers GJ; van Rooijen JM; Los M; Vulink AJE; Schut H; van Meerten E; Baars A; Hamberg P; Kapiteijn E; Sommeijer DW; Punt CJA; Koopman M
    Int J Clin Oncol; 2018 Jun; 23(3):482-489. PubMed ID: 29204933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.